Company Description
Ainos, Inc., a healthcare company, focuses on the development of novel point-of-care testing therapeutics based on very low-dose interferon alpha and synthetic RNA-driven preventative medicine.
The company provides COVID-19 antigen rapid test kit and VELDONA pet supplement, a health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues.
It offers VELDONA human and animal drugs, a human drug pipeline includes treatments for oral warts in HIV-seropositive patients, Sjögren’s syndrome, common cold, and influenza; VOC POCT – Ainos Flora designed to offer a quick, non-invasive test for female vaginal health and common STIs; and VOC platform – NISD co-development sensing platform based on AI Nose.
In addition, the company provides VOC POCT – Ainos Pen, a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions within minutes; VOC POCT – CHS430 provide non-invasive testing for ventilator-associated pneumonia within few minutes, as compared to current standard of care invasive culture tests that typically take more than two days to provide results; and Synthetic RNA develops a SRNA technology platform in Taiwan.
The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.
The company was incorporated in 1984 and is based in San Diego, California.
| Country | United States |
| Founded | 1984 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Chun-Hsien Tsai |
Contact Details
Address: 8880 Rio San Diego Drive, Suite 800 San Diego, California 92108 United States | |
| Phone | 858 869 2986 |
| Website | ainos.com |
Stock Details
| Ticker Symbol | AIMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001014763 |
| CUSIP Number | 00902F105 |
| ISIN Number | US00902F3038 |
| Employer ID | 75-1974352 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chun-Hsien Tsai | Chief Executive Officer, President and Chairman of the Board |
| Hsin-Liang Lee | Chief Financial Officer |
| Chih-Heng Lu | Director of Corporate Developoment |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 8-K | Current Report |
| Mar 12, 2025 | SCHEDULE 13D/A | Filing |
| Mar 12, 2025 | SCHEDULE 13D/A | Filing |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 10-K | Annual Report |
| Mar 5, 2025 | 8-K | Current Report |
| Dec 31, 2024 | EFFECT | Notice of Effectiveness |
| Dec 30, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |